TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Living in the United States (contiguous states)~* Aged 21 years or older~* Able to provide documentation of +Polymerase Chain Reaction (PCR) or +antigen test for COVID-19 within the past 48 hours~* Self-reports that comfortable and willing to wear the wearable device and interact with a tablet-based interface daily~* Able to provide a next of kin/designated person who can be contacted in the event of hospitalization for follow up.~Exclusion Criteria:~* Under the age of 21~* Received a positive test result more than 48 hours prior to contacting study staff or has a pending test for COVID-19~* Cannot confirm a PCR or antigen positive test for COVID-19~* Is unable to read English~* Is unwilling to wear the device 24 hours/day except for showering/bathing or interact with a tablet-based interface for daily questionnaire~* Is unwilling or unable to provide baseline data required for entry into the study~* Is unable to provide a next of kin/designated person who can be contacted in the event of hospitalization for follow-up~* Heavy tattooing on both upper arms~* Known atrial fibrillation (permanent or paroxysmal)~* Has taken/is taking part in a COVID-19 vaccine or treatment trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID19+ (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of tDCS Efficacy in Enduring Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 anorexia nervosa criteria~* Body Mass Index (BMI) \< 17kg/m2~* Conventional treatment failure over the last 12 months~* Refusal or no indication of artificial nutrition~Exclusion Criteria:~* Artificial nutrition~* Other chronic diseases~* drug use (except tobacco)~* pregnancy~* Edinburgh score \< 14

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active stimulation (Type: EXPERIMENTAL): Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with active stimulations
- Sham stimulation (Type: SHAM_COMPARATOR): Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with inactive stimulations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measuring the Impact of an Innovative Educational Intervention in Inflammatory Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years and had a diagnosis of RA,~* with active disease as per rheumatologist evaluation,~* having received a trial of two traditional nbDMARDs therapy, and~* who requires the addition or change of a biological agent~Exclusion Criteria:~* patient unable to consent,~* patient unable to answer questionnaires,~* patient unable to view a DVD at home~* patient unable to participate in a teleconference

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm1, Participants received the multidisciplinary educational intervention at baseline (Type: ACTIVE_COMPARATOR): Participants in arm1 received the usual care plus the multidisciplinary educational intervention consisting of an educational DVD followed by a teleconference at baseline.
- Arm2, Participants in arm2 received the educational intervention after 3 months (Type: OTHER): Participants in group 2 first received usual care, and after 3 months were offered the multidisciplinary educational intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Testicular Cancer and Aerobic and Strength Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* testicular cancer with seminoma or non-seminoma~* stage II-IV~* referred to chemotherapy (3-4 BEP (bleomycin, etoposide and cisplatin)-cycles or 4 EP (etoposide and cisplatin) -cycles) with/without retroperitoneal lymph node dissection (RPLND)~* satisfactory Norwegian Language skills~* signed informed consent~Exclusion Criteria:~* severe brain and lung metastasis (reduced lung function)~* heart and lung diseases that contraindicate exercise testing and the supervised exercise program without adjusted actions according to American College of Sports Medicine (ACSM)'s guidelines)~* physical and mental conditions of a severity that complicates the ability for exercise testing and the supervised exercise program

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Exercise group (Type: EXPERIMENTAL): Aerobic- and Strength Training program
- Control group (Type: ACTIVE_COMPARATOR): One lifestyle counseling session

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Remediation in Youth at Risk of Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants aged 14-25 years with subthreshold mood and psychotic symptoms.~Exclusion Criteria:~* (i) meet criteria for current or lifetime Axis I bipolar or psychotic disorder (other Axis I disorders will not be exclusionary as they may be precursors to mood or psychotic disorders);~* (ii) IQ \< 70;~* (iii) past or current history of a significant central nervous system disorder or serious medical disorder; and~* (iv) current pharmacological treatment that would be considered as an adequate trial of treatment for a SMI.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- cognitive remediation treatment and MI (Type: EXPERIMENTAL): Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
- cognitive remediation treatment (Type: ACTIVE_COMPARATOR): Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Actinic keratosis lesion located in any of the following body sites:~  * Stratum 1\*: face and neck, scalp, or upper torso~    * At least 1 clinically evident thin actinic keratosis on each side of the midline of any of the above areas~ * Stratum 2\*: arms or legs~    * At least 1 clinically evident thick actinic keratosis on each arm or leg NOTE: \*One patient may be in one or both strata depending on the location of the lesion(s)~* Lesions to be treated on this protocol must not have been previously treated by other modalities for at least 2 months prior to study entry~PATIENT CHARACTERISTICS:~* No porphyria or known hypersensitivity to porphyrins~* No known photosensitivity disease~* No known sensitivity to any components of aminolevulinic acid topical solution~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~* Other concurrent topical therapies at lesion sites other than those used in this protocol are allowed~* No other concurrent photosensitizer drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 - ALA (Type: EXPERIMENTAL): Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
- Arm 2 (Type: EXPERIMENTAL): Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
- Arm 3 (Type: EXPERIMENTAL): Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
- Arm 4 (Type: EXPERIMENTAL): Vbeam laser pulse (photodynamic therapy) is applied to the subunit
- Arm 5 (Type: EXPERIMENTAL): Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional Near Infra-Red Spectroscopic Study of Central Auditory System Cortical Functional Reorganization

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~For both groups:~* 5 to 16 year-old children,~* Absence of pregnancy~* Affiliation to Social Security, and children and their parents signed consents will be necessary.~* Participation agreement of the protocol and signature of the consent form by the person having parental authority and the child~For Single-sided Deafness subjects:~- shall present with moderate to profound unilateral hearing loss, with a hearing loss of 40 decibel(minimal thresholds), assessed on tonal, vocal audiometry, Auditory Brainstem Responses,~For Normal hearing subjects:~- shall have normal hearing, demonstrated by air thresholds below 20 decibel by an audiometric control before inclusion , matched in gender and age to children in the experimental group~Exclusion Criteria:~For both groups:~* Antecedents of Psycho-neurological diseases,~* Other sensorineural or motor deficiency,~* Familial bilingualism,~* Medications affecting vigilance.~* pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Single-sided deaf group (Type: EXPERIMENTAL): 30 children will be included in this group
- Normal hearing group (Type: ACTIVE_COMPARATOR): 30 children will be included in this group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitreous Surgery With Intraocular Assistance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must meet the following criteria to be eligible for study entry:~* Signed informed consent and authorization of use and disclosure of protected health information~* Age ≥18 years~* Subject will have complex retinal pathology for which it is judged that surgical objectives could be facilitated by VISIA~Exclusion Criteria:~Subjects who meet any of the following criteria will be ineligible for study entry:~• Patients with disease processes such as macular pucker and macular hole that are generally well-managed by standard two-handed vitrectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Intraocular Assistance (Type: EXPERIMENTAL): Intraocular assistance in patients undergoing standard of care vitreous surgeries

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults 18 years or older with documented MDS (including MDS-subtype, CMML) or AML (as defined by WHO criteria)~2. Severe thrombocytopenia defined as a platelet count of ≤ 10 x 109/L documented on two consecutive samples at least 7 days apart.~3. Receiving outpatient-based supportive or palliative care including palliative cytoreductive, immunomodulatory or hypomethylating therapy, e.g. hydroxyurea or low dose cytarabine, lenalidomide, azacytidine, or decitabine.~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.~Exclusion Criteria:~1. High-dose therapy in past 2 months, e.g. AML-type induction or consolidation therapy~2. Thrombocytopenia suspected to be due to immune or peripheral destruction~3. Splenomegaly, palpated at greater than 5 cm below the costal margin or greater than 20 cm on imaging~4. Alloimmune platelet refractoriness~5. Clinically relevant bleed (grade 3 or higher) within the past 3 months~6. Coagulopathy (prothrombin time or activated partial thromboplastin more than 1.5 times the upper limit of normal or fibrinogen less than 2 g/L)~7. Require anticoagulant therapy, e.g. heparin, or antiplatelet therapy, e.g. aspirin~8. Significant renal impairment (Creatinine more than 1.5 times the upper limit of normal)~9. Geographic inaccessibility resulting in the inability to comply with follow-up visits~10. Pregnant or breast-feeding~11. Unwilling or unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Platelet Transfusion Arm (Type: EXPERIMENTAL): Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
- Prophylactic Platelet Transfusion Group (Type: ACTIVE_COMPARATOR): Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is \< 10 x 109/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Formal Home Help on Quality of Life for Caregivers of Elderly Patients With Neurocognitive Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patient 60 years of age or older~* Diagnosis of neurocognitive disorders~* MMSE score less than or equal to 26~* GIR score inferior or equal to 4~* Introduction of formal home help (personalized autonomy allowance for seniors program)~* Patient living in Haut-Rhin department (France)~* Patient receiving regular informal help at home (at least once a week)~* Availability of the current home helper to participate in the sudy~* Non-opposition to participation in the study~Exclusion criteria:~* Introduction of formal home care not related to the personalized autonomy allowance program~* Patient under legal protection

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a partial response (PR) or better prior to allo-transplantation~* Relapsed MM with chemo sensitivity disease, with or without prior autologous HSCT~* First allogenic transplant~* Donors can be haploidentical, mismatch or matched related or unrelated. Stem cell source will be peripheral blood except for haploidentical where stem cell source will be bone marrow~* Ejection fraction \>= 45%~* Estimated creatinine clearance greater than 40 mL/minute~* Diffusion capacity of the lung for carbon monoxide (DLCO) \>= 40% (adjusted for hemoglobin)~* Forced expiratory volume in 1 second (FEV1) \>= 50%~* Total bilirubin \< 2 x the upper limit of normal~* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \< 2.5 x the upper normal limit~* Signed informed consent~Exclusion Criteria:~* Patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin change (POEMS), Waldenstrom macroglobulinemia~* Uncontrolled bacterial, viral or fungal infection~* Patients with prior malignancies \< 3 years except resected basal cell/squamous cell carcinoma, treated carcinoma in-situ. Other cancers treated with curative intent \< 3 years previously will not be allowed unless approved by the principal investigator~* Female patients who are pregnant or breastfeeding. A negative pregnancy test will be required for all women of child bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (conditioning regimen, stem cell transplant) (Type: EXPERIMENTAL): Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient verbally consents to participation~* Patient is willing to have heart sounds recorded with an electronic stethoscope~* Patient is age 50 years or older~Exclusion Criteria:~* Patient is unwilling or unable to give verbal informed consent~* Patients experiencing a known or suspected acute cardiac event~* Patient is under the age of 50 years old

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prospective cohort (Type: None): Patients who are at least 50 years of age during their primary care exam will undergo SENSORA™ screening if they provide consent.
- Retrospective cohort (Type: None): Patients who saw participating providers in the 6 months prior to study start date, and who were referred to echocardiogram and/or cardiology, will be included as provider self-control for patient outcomes and referral rates.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Foot Strengthening Protocol on Sport Performance Kinetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* To be affiliated in the federation of one of the following sports : soccer, handball, rugby, basketball or track and field;~* To practice their respective sport more than two times per week;~* Be affiliated or beneficiary of a social security insurance;~* Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved.~* Licensed in a tennis club (FFT) and in a volleyball club (FFVolley)~Exclusion criteria :~* Use of pharmacological therapy to match gander identity;~* Have an abnormal range of motion of the toes and/or ankle;~* Have any kind of ankle or foot pain (self-defined and self-reported by the FAAM questionnaire) in the previous 6 months;~* Have a previous injury or surgery of the lower limb in the previous 6 months;~* Have a neurological or vestibular deficit that may affect walking or balance (lumbar-sacral radiculopathy, peripheral nerve pathology, Marfan or Eehlers-Danlos syndrome, etc.);~* Have contraindication to neuromuscular electrical stimulation (pacemaker, seizure disorders, pregnancy);~* Have a previous foot strengthening experience in the past 6 months for at least 2 weeks and more than one session per week;~* Participate at the same time in another medical interventional experiment or have participated in such a study in the 30 days preceding this study;~* Being unable to understand the purpose and conditions of the study, and to give consent;~* Being deprived of liberty or under guardianship.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Training group (PRP) (Type: EXPERIMENTAL): Participants benefiting from an 8-week muscle strengthening program (PRP)
- Control group (Type: SHAM_COMPARATOR): Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues